Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Metsera Inc.’s shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would ...

Metsera (NASDAQ:MTSR) added ~16% on Tuesday as Wall Street continued to cheer early-stage trial data the company posted for ...

Metsera stock surged Monday after the drugmaker unveiled "solid" results for a potential monthly shot to stoke weight loss.

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...

Metsera, the obesity-focused biotech, said this morning that its drug candidate targeting the amylin hormone showed marked ...

An experimental Metsera obesity drug led to an average 8.4% weight loss in a small clinical trial, preliminary results that keep the biotech competitive in the crowded mix of companies pursuing a ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...

Metsera's shares, which touched $35.19 in early trading, were up 5% at midday. The first wave of obesity drugs was based mainly on the gut hormone GLP-1, but drugmakers are looking for medicines ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.